GlassScriptPhysician profile
Vinnie Law
NPI 1730643925
$4,972.09
in general payments reported to CMS, 2019-2025
30 companies · $927 in 2025
The $927 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $803 · 2023: $1,380 · 2024: $1,383 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,690.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $480.45 | 2023-2025 | Farxiga, Wainua, Datroway |
| Abbvie INC. | $326.00 | 2021-2024 | |
| Hologic Sales and Service, LLC | $294.15 | 2023-2025 | Aptima |
| Madrigal Pharmaceuticals | $285.17 | 2024-2025 | Rezdiffra |
| Jazz Pharmaceuticals INC. | $265.94 | 2023-2025 | |
| Novo Nordisk INC | $246.83 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $234.33 | 2022-2024 | Austedo Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $225.11 | 2022-2023 | Jynarque |
| Neurelis, INC. | $220.76 | 2022-2023 | Valtoco |
| Inspire Medical Systems, INC. | $168.05 | 2025 | Inspire |
| Abbott Laboratories | $164.37 | 2023 | Infinity |
| Edwards Lifesciences Corporation | $149.62 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $133.82 | 2023 | Relyvrio |
| Boston Scientific Corporation | $133.81 | 2023 | |
| Genzyme Corporation | $133.12 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $127.88 | 2024 | Onpattro |
| Shield Therapeutics INC | $125.01 | 2022 | |
| Lundbeck LLC | $124.73 | 2022 | |
| Genentech USA, INC. | $122.90 | 2021 | |
| Argenx US, INC. | $122.64 | 2024 | Vyvgart |
| Glaxosmithkline, LLC. | $118.08 | 2024 | |
| Stryker Corporation | $108.93 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Idorsia Pharmaceuticals US INC | $108.21 | 2023 | Quviviq |
| Emd Serono, INC. | $101.05 | 2025 | |
| Aspira Women'S Health INC | $97.63 | 2024 | Ova1 |
| Amarin Pharma, INC. | $97.47 | 2024 | |
| Amgen INC. | $93.19 | 2021 | |
| Scynexis, INC. | $77.39 | 2022 | |
| Fresenius Kabi USA, LLC | $66.55 | 2024 | Idacio |
| Merck Sharp & Dohme LLC | $18.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinnie Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.